IMMUNOENHANCING ANTIGEN RE-ENGINEERING PLATFORM FOR VACCINES & IMMUNOTHERAPIES DEVELOPMENT

IMX313 is a short DNA sequence fused to the antigen gene. When the recombinant antigen is expressed as a protein, it spontaneously forms a heptamer, which makes it more visible to the immune system, and highly increases both B & T cell immune responses against the original antigen.

IMX313 is compatible with subunit, DNA and viral vectors delivery systems, but also synergistic with conventional adjuvant technologies.

IMX313 is a proprietary technology of IMAXIO, wich generates IP for recombinant antigens developed on the platofrm.

 

 

 

PROOFS OF CONCEPT

  PIPELINE & COLLABORATIONS




In order to pursue the development of its proprietary technology IMX313, IMAXIO is searching for new collaborations to develop vaccines & immunotherapies in addtional indications, and is looking in particular for partners who have know-how on antigens with a lack of immunogenicity. Please, feel free to contact us for more information.




REFERENCES

• T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein. Emily K. Forbes, Simone C. de Cassan, David Llewellyn, Sumi Biswas, Anna L. Goodman, Matthew G. Cottingham, Carole A. Long, Richard J. Pleass, Adrian V. S. Hill, Fergal Hill, Simon J. Draper. PLoS ONE. 2012 September;7(9):e44943.

• Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates. Spencer AJ, Hill F, Honeycutt JD, Cottingham MG, Bregu M, Rollier CS, Furze J, Draper SJ, Søgaard KC, Gilbert SC, Wyllie DH, Hill AVS. PLoS ONE. 2012 March;7(3): e33555. doi:10.1371/journal.pone.0033555.

 

• The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria. Ogun SA, Dumon-Seignovert L, Marchand JB, Holder AA, Hill F. Infect Immun. 2008 Aug;76(8):3817-3823.

• Effective induction of high-titer antibodies by viral vector vaccines. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, Hill F, Hill AV. Nat Med. 2008 Aug;14(8):819-821.